Risedronate

Older adults who sustain a hip fracture after discontinuing risedronate following at least 5 years of treatment adherence have a higher post-fracture mortality risk than those who continue using risedronate, according to study data.

Postmenopausal women with low bone mass saw greater gains in spine bone mineral density and less bone turnover when assigned monthly risedronate therapy compared with a 12-month regimen of impact and resistance exercises, study data show.